Viral Inactivation segmentation by Application delineates four primary end‑use categories that together drive the market’s revenue profile. Blood products—including plasma, red‑cell concentrates, and platelets—represent the largest share, accounting for roughly 35 % of total spend, because stringent regulatory mandates require validated pathogen‑reduction steps across transfusion pipelines. Vaccines occupy the second tier (≈30 %), as manufacturers embed inactivation stages to ensure safety of live‑attenuated and subunit formulations, particularly for emerging infectious diseases. Gene‑therapy vectors contribute about 20 % of the market; the high‑value, low‑volume nature of viral vectors necessitates precise, often proprietary, inactivation protocols to balance potency preservation with biosafety. Finally, cell‑therapy products make up the remaining 15 %, where cell‑based bioprocesses integrate viral clearance methods to meet GMP standards for autologous and allogeneic treatments. Collectively, these application segments define the demand curve for equipment, consumables, and validation services, establishing the quantitative foundation of the overall Viral Inactivation market.